OICR funds four Ontario teams to develop next-generation cancer therapies
Better cancer care depends on better treatment options. That’s why the Ontario Institute for Cancer Research (OICR) is…
CTDNEP1 identified as potential tumor suppressor in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining…